ARQT MEXC RealStocks
Own real ARQT shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:04:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Arcutis Biotherapeutics, Inc. (ARQT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $27.60, with a market capitalization of $3.43B and a P/E ratio of 115.55. Over the past 52 weeks, its price has ranged from $19.30 to $34.80. This page covers its latest market performance, valuation, price trends and company information.
$3.43B | |
$27.42 | |
$28.01 | |
$26.64 | |
$27.33 | |
631.89K | |
2.65M | |
115.55 | |
$34.80 | |
$19.30 | |
-- | |
2026-09-30 |
Arcutis Biotherapeutics, Inc. (ARQT) last closed at $27.60 as of 2026-11-19 00:31:00, up 1.02% ($0.28) from the previous close of $27.33.
During the latest regular trading session, ARQT traded between $26.64 and $28.01, with a volume of 631.89K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Arcutis Biotherapeutics, Inc. (ARQT) moved from $26.20 to $27.60, representing a gain of 5.36% ($1.40).
The stock traded between $25.23 and $28.94 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.89 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 53.6%
ARQT is currently trading at $27.60, placing it 53.6% of the way from its 52-week low of $19.30 to its 52-week high of $34.80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 354 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arcutis Biotherapeutics, Inc. (ARQT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ARQT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ARQT shares and USD.
ARQT Shares to USD
1.00 ARQT shares = 27.604 USD
Calculations are estimates based on the latest available price and are for reference only.